

In the claims:

Please cancel claims 1-90 and add the following new claims:

91. A method for preventing or inhibiting inflammatory disease in a patient in need thereof, comprising the administration of an effective amount of a PTEN agonist.

92. The method as claimed in claim 91, wherein said inflammatory disease is selected from the group consisting of macular degeneration, arthritis, asthma, hay fever, systemic lupus erythematosus, Crohn's disease, and inflammatory bowel disease.

93. The method as claimed in claim 91, further comprising the administration of an inhibitor of PI-kinase.

94. The method as claimed in claim 93, wherein said PI-kinase inhibitor is LY294002.

95. The method as claimed in claim 91, further comprising the administration of an AKT inhibitor.

96. The method of claim 91, wherein said agonist inhibits immunoreceptor signaling.

97. The method as claimed in claim 96, wherein said immunoreceptor is selected from the group consisting of a T cell receptor, a B cell receptor, an ITAM-bearing receptor, a Fcγ receptor, a FCεRI receptor, and a FcαRI receptor.

98. The method as claimed in claim 96, wherein said agonist inhibits Fcγ receptor mediated phagocytosis.

99. The method of claim 96, wherein said agent modulates ITAM-bearing receptor signaling.

100. The method of claim 99, wherein said ITAM signal is selected from the group consisting of T cell receptor/CD3 complex signaling in T cells, B cell receptor signaling in B cells, Fcγ receptor signaling, FCεRI receptor signaling in mast cells and FcαRI signaling.

101. The method of claim 91 wherein said agent is administered via a route selected from the group consisting of intravenous administration, oral administration, and topical administration.

REMARKS

The purpose of this preliminary amendment is to 1) insert a priority claim into the application, and 2) present new claims.